Journal Club

 

2020

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial23.11.2020 (Silvio Ragozzino)
Ramasamy MN, et al.: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Lancet Published online November 19, 2020
A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis16.11.2020 (Sabine Kuster)
CODA Collaborative, Flum DR, Davidson GH, Monsell SE, et al.: A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis N Engl J Med 2020 Nov 12;383(20 1907-1919

1) Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other enterococcal Species by the clinical and Laboratory Standarts Institute
2) Daptomycin in the treatment of enterococcal bloddstream infections and endocarditis: a EUCAST position paper


09.11.2020 (Seraina Bally)
1) Michael J. Satlin 2) J. Turnidge et al.:
1) Michael J. Satlin, Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other enterococcal Species by the clinical and Laboratory Standards Institute, CID 2020
2) J. Turnidge et al., Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper, Clinical Microbiology and Infection 2020
 

1) Longitudinal oberservation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans 2) SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 02.11.20 (Ana Durovic)   
1) Seow J. et al 2) Chen P et al: 1)Longitudinal oberservation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
2) SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
1) Nature microbiology 2) NEJM DOI: https://doi.org/10.1038/s41564-020-00813-8
DOI : 10.1056/NEJMoa2029849 2020
Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results19.10.2020 (Sandra Zingg)      
Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results MedRxiv preprint 2020
Self-Collected Anterior Nasal and Saliva 1 Specimens versus Healthcare Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-212.10.2020 (Kai-Manuel Adam)
Hanson KE et. al.: Self-Collected Anterior Nasal and Saliva 1 Specimens versus Healthcare Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2 J. Clin. Microbiol. Epub Epub 2020
Individual quarantine versus active monitoring of contact for the mitigation of COVID-19: a modelling study14.09.2020 (Matthias von Rotz)
Peak CM. et al.: Individual quarantine versus active monitoring of contact for the mitigation of COVID-19: a modelling study Lancet Infect Dis 20: 1025-33 2020
1. Setting The criteria for SARS-CoV-2 Reinfection – six Possible cases
2. Clinical recurrences of COVID-19 Symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
3. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

07.09.2020 (Kai-Manuel Adam)
Diverse 3. Paper: 1. Setting The criteria for SARS-CoV-2 Reinfection – six Possible cases
2. Clinical recurrences of COVID-19 Symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
3. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing J Infect; CID Epub Epub 2020

Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species31.08.2020 (Ana Durovic)
Chamat-Hedemand S. et al.: Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species Circulation Volume 142, Issue 8 720-730 2020
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study 24.08.2020 (Sandra Zingg)
Iversen K. et al.: Risk of COVID-19 in health-care workers in Denmark: an observational cohort study Lancet Infect Dis 2020 S1473-3099(20)30589-2 2020
Molecular epidemiology of resistance  to antimalarial drugs in the greater Mekong subregion: an observational study17.08.2020 (Mihaela Sava)
Imwong M. et al.: Molecular epidemiology of resistance  to antimalarial drugs in the greater Mekong subregion: an observational study        THE LANCET Infectious Diseases Epub Epub 2020 Juli
Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use10.08.2020 (Anne-Valérie Burgener)
Rhee, Kadri, Dekker et al.: Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use JAMA Infect. Disease, 2020;3(4):e202899
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts03.08.2020 (Silvio Ragozzino)
Ikematsu H. et al.: Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts N Eng J Med 383 309-320 2020
Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. A Randomized Clinical Trial27.07.2020 (Matthias von Rotz)
von Dach E. et al.: Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. A Randomized Clinical Trial JAMA 323, Number  21 2160-2169 June 2, 2020
An mRNA Vaccine against SARS-CoV-2 – Preliminary Report20.07.2020 (Sabine Kuster)
Jackson L.A. et al.: An mRNA Vaccine against SARS-CoV-2 – Preliminary Report NEJM  July 14, 2020 DOI:10.1056/NEJMoa2022483 1-12
Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report13.07.2020 (Sandra Zingg)
Peter Horby: Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report medRvix preprint https://doi.org/10.1101/2020.06.22.20137273 2020
Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial29.06.2020 (Sabine Kuster)
Deftereos S.G. et al: Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial JAMA Online June 2020, Vol 3, No. 6 1 -14 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial22.06.2020 (Mihaela Sava)
Zhu FC et al.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial The Lancet 395 1845-54
2020 Mai
1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
15.06.2020 (Kai-Manuel Adam)
Diverse 3 Paper:
1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
medRxiv preprint Epub Epub 2020 Juni
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis08.06.2020 (Matthias von Rotz)
Mehra MR. et al.: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis The Lancet Nur online erschienen. 22. Mai 2020
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study25.05.2020 (Aurélien Emmanuel Martinez)
Verdoni L. et al.: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Lancet Online online 2020
Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure18.05.2020 (Ana Durovic)
Kucirka L.M. et al.: Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure ACP Journals doi.org/10.7326/M20-1495 2020
Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies11.05.2020 (Anne-Valérie Burgener)
Williams CM et al.: Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies Lancet Infect Dis. Volume 20 607-617
An analysis of SARS-CoV-2 viral load by patient age04.05.2020 (Silvio Ragozzino)
Terry CJ. et al: An analysis of SARS-CoV-2 viral load by patient age
Preprint – https://virologie-ccm.charite.de/
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial20.04.2020 (Sandra Zingg)
Mahévas M. et al: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial BMJ (medRxiv) 04/2020
Virological assessment of hospitalized patients with COVID-1906.04.2020 (Mihaela Sava)
Wölfel R et al.: Virological assessment of hospitalized patients with COVID-19
Nature 2020, published online April 1st , 2020
Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents30.03.2020 (Matthias von Rotz)
Kampf G. et al.: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents Journal of Hospital Infection 104 246-251 2020
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study10.02.2020 (Sabine Kuster)
Nashan Chen et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet Infectious Disease Published Online January 29, 2020 1-7 2020
Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial20.01.2020 (Elisabeth Wehrle)
Kaye K.: Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial CID 69 2045-2056 2019
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials13.01.2020 (Mihaela Sava)
Campbell R J. et al.: Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials Lancet Infect Dis 2019 Online First 2019
Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in 
critically ill
06.01.2020 (Sandra Zingg)
Gloria Wong: Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in critically ill J Antimicrob Chemother 75 429-433 2020